GlobeNewswire News Room·2025-07-20 12:34Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Biohaven Ltd. securities, alleging misleading statements regarding the company's drug regulatory prospects and clinical efficacy during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025 [1]. - Allegations include that Biohaven overstated the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which could negatively impact the company's business and financial condition [5]. Group 2: Participation Information - Investors who purchased Biohaven securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].